Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.
Authors
Susanna Varkey Ulahannan
University of Okahoma Health Sciences Center, Oklahoma City, OK
Susanna Varkey Ulahannan , Melissa Lynne Johnson , Mia C. Weiss , Andrae L. Vandross , Sofia Luz Vidal-Cardenas , Mustafa Syed , Anthony W. Tolcher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04925284
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS421)
DOI
10.1200/JCO.2024.42.3_suppl.TPS421
Abstract #
TPS421
Poster Bd #
N6
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors.
First Author: Luis Teixeira
Poster
2024 ASCO Annual Meeting
A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
First Author: Toshihiko Doi
Poster
2024 ASCO Genitourinary Cancers Symposium
Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor–targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.
First Author: Susanna Varkey Ulahannan
Poster
2023 ASCO Annual Meeting
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
First Author: Antoine Hollebecque